The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
An article from
Startup launches
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
Published May 20, 2026
Vadym Plysiuk via Getty Images
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
In this week’s edition of InnovationRx, we look at Town Hall Ventures’ $440 million haul, the CDC’s “Friday night massacre,”…
Amplia Therapeutics has launched a pivotal registration-enabling trial of narmafotinib for pancreatic cancer, testing better…
Blackstone Life Sciences is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of…
Amplia takes aim at billion-dollar pancreatic cancer drug market
